
JAK
JAK (Janus kinase) inhibitors are compounds that target the JAK-STAT signaling pathway, which is involved in cell growth, immune response, and angiogenesis. By inhibiting JAK, these compounds can reduce the signaling that leads to the formation of new blood vessels in tumors, thereby inhibiting tumor growth. JAK inhibitors are important in the treatment of cancers and inflammatory diseases. At CymitQuimica, we offer a diverse range of high-quality JAK inhibitors to support your research in oncology, immunology, and angiogenesis.
Found 245 products of "JAK"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
XL019
CAS:<p>XL019 is a potent and selective JAK2 inhibitor with IC50 of 2.2 nM, 100 fold selectivity over JAK1.</p>Formula:C25H28N6O2Purity:99.19%Color and Shape:SolidMolecular weight:444.532,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide
CAS:<p>2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide (GDC046), a potent lead analog, has good kinase selectivity and physicochemical properties.</p>Formula:C16H13Cl2N3O2Purity:98.77%Color and Shape:SolidMolecular weight:350.2Cerdulatinib
CAS:<p>Cerdulatinib (PRT2070) is an novel oral dual Syk/JAK inhibitor.</p>Formula:C20H27N7O3SPurity:98.74% - 99.49%Color and Shape:SolidMolecular weight:445.54Protosappanin A
CAS:<p>Protosappanin A combats brain inflammation, suppresses rat heart transplant rejection, fights MRSA, and inhibits HIV with a 12.6 uM IC50.</p>Formula:C15H12O5Purity:99.42% - 99.82%Color and Shape:SolidMolecular weight:272.25AMG-47a
CAS:<p>AMG-47a inhibits Lck, T cell growth, and degrades KRAS oncoprotein, affecting EGFP-KRASG12V but not EGFP.</p>Formula:C29H28F3N5O2Purity:98%Color and Shape:SolidMolecular weight:535.56Decernotinib
CAS:<p>Decernotinib (VRT-831509)(VX-509; VRT-831509) is a potent and selective Janus kinase 3 (JAK3) inhibitor with Ki of 2.5 nM; IC50 is 50-170 nM in cellular assays.</p>Formula:C18H19F3N6OPurity:99.28% - >99.99%Color and Shape:SolidMolecular weight:392.38G5-7
CAS:<p>G5-7 is an oral JAK2 inhibitor targeting EGFR/STAT3 phosphorylation with potential for glioma research.</p>Formula:C22H19F2NO3Purity:97.3%Color and Shape:SolidMolecular weight:383.39(E/Z)-Zotiraciclib
CAS:<p>(E/Z)-Zotiraciclib ((E/Z)-TG02) inhibits CDK2, JAK2, and FLT3 effectively with IC50s of 13, 73, and 56 nM, respectively.</p>Formula:C23H24N4OPurity:97.75% - 99.92%Color and Shape:SolidMolecular weight:372.46FLLL32
CAS:<p>FLLL32 is an effective JAK2/STAT3 inhibitor (IC50 of <5 μM).</p>Formula:C28H32O6Purity:97% - 97.90%Color and Shape:SolidMolecular weight:464.55AG490
CAS:<p>AG490 inhibits EGFR (0.1 μM IC50), 135x > selective than ErbB2, blocks JAK2, spares Lyn, Lck, Syk, Btk, Src.</p>Formula:C17H14N2O3Purity:98.6% - 99.39%Color and Shape:Yellow SolidMolecular weight:294.3GDC-0214
CAS:<p>GDC-0214 is an inhaled small-molecule JAK1 inhibitor and reduces fractional exhaled nitric oxide (Feno).</p>Formula:C28H28ClF2N9O3Purity:99.75%Color and Shape:SolidMolecular weight:612.03Baricitinib
CAS:<p>Baricitinib (INCB028050) is an orally JAK1 and JAK2 inhibitor. Baricitinib has anti-inflammatory and anti-tumor activity. Cost-effective and quality-assured.</p>Formula:C16H17N7O2SPurity:99% - >99.99%Color and Shape:SolidMolecular weight:371.42Peficitinib
CAS:<p>Peficitinib (ASP015K) (ASP015K, JNJ-54781532) is an orally bioavailable JAK inhibitor. Phase 3.</p>Formula:C18H22N4O2Purity:98.67% - 99.4%Color and Shape:SolidMolecular weight:326.39Pyridone 6
CAS:<p>Pyridone 6, a selective JAK1/2/3 and Tyk2 inhibitor with IC50s: JAK1=15 nM, JAK2=1 nM, JAK3 (Ki=5 nM), Tyk2=1 nM; weakly binds other kinases (130 nM-10 μM).</p>Formula:C18H16FN3OPurity:97.1% - 98.74%Color and Shape:SolidMolecular weight:309.34WHI-P97
CAS:<p>WHI-P97 is a rationally designed potent inhibitor of JAK-3.</p>Formula:C16H13Br2N3O3Purity:99.93%Color and Shape:SolidMolecular weight:455.1JANEX-1
CAS:<p>JANEX-1: cell-permeable, reversible Jak3 inhibitor (IC50: 78 μM), ATP-competitive, selective; weak on JAK1/2, Zap/Syk, SRC.</p>Formula:C16H15N3O3Purity:98% - 99.81%Color and Shape:SolidMolecular weight:297.31WP1066
CAS:<p>WP1066 is a inhibitor of JAK2 (IC50: 2.30 μM) and STAT3 (IC50: 2.43 μM) in HEL cells; shows activity to JAK2, STAT3/5, and ERK1/2, not JAK1 and JAK3.</p>Formula:C17H14BrN3OPurity:98.92% - 99.73%Color and Shape:SolidMolecular weight:356.22Fedratinib hydrochloride hydrate
CAS:<p>Fedratinib hydrochloride hydrate (SAR 302503 hydrochloride hydrate) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor.</p>Formula:C27H40Cl2N6O4SPurity:98.96% - 99.87%Color and Shape:SolidMolecular weight:615.61AZ960
CAS:<p>AZ960 is an effective ATP competitive JAK2 inhibitor (IC50/Ki: <3 nM and0.45 nM).</p>Formula:C18H16F2N6Purity:96.02% - 98.51%Color and Shape:SolidMolecular weight:354.36ZM39923 hydrochloride
CAS:<p>ZM39923 hydrochloride (JAK3 Inhibitor IV) is an JAK1/3 inhibitor, almost no activity to JAK2 and modestly potent to EGFR; also is sensitive to transglutaminase.</p>Formula:C23H25NO·HClPurity:98.05%Color and Shape:SolidMolecular weight:367.91BMS-911543
CAS:<p>BMS-911543 is a potent and selective inhibitor of JAK2 with IC50 of 1.1 nM, ~350-, 75- and 65-fold selective to JAK1, JAK3 and TYK2, respectively. Phase 1/2.</p>Formula:C23H28N8OPurity:97.69% - 99.98%Color and Shape:SolidMolecular weight:432.52SAR-20347
CAS:<p>SAR-20347 is an inhibitor of TYK2, JAK1/2/3 (IC50: 0.6/23/26/41 nM).</p>Formula:C21H18ClFN4O4Purity:98.99% - 99.77%Color and Shape:SolidMolecular weight:444.84FM-381
CAS:<p>FM381, a JAK3 inhibitor with 127 pM IC50, is 410-3600x more selective over JAK1/2/TYK2.</p>Formula:C24H24N6O2Purity:98.44%Color and Shape:SolidMolecular weight:428.49TG101209
CAS:<p>TG101209 is a selective JAK2 inhibitor with IC50 of 6 nM.</p>Formula:C26H35N7O2SPurity:99% - >99.99%Color and Shape:SolidMolecular weight:509.67Deucravacitinib
CAS:<p>Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable, allosteric TYK2 inhibitor.Cost-effective and quality-assured.</p>Formula:C20H19D3N8O3Purity:98.52% - >99.99%Color and Shape:SolidMolecular weight:425.46RO495
CAS:<p>RO495 (CS-2667), a potent inhibitor of TYK2, inhibits TYK2 with IC50 of 1.5nM as tested in cell-based pharmacological assays</p>Formula:C17H14Cl2N6OPurity:97.94%Color and Shape:SolidMolecular weight:389.24SC99
CAS:<p>SC99 inhibits JAK2-STAT3, reducing STAT3 genes, platelet activity, and has anti-myeloma, anti-thrombotic effects.</p>Formula:C15H8Cl2FN3OPurity:99.56%Color and Shape:SolidMolecular weight:336.15Brevilin A
CAS:<p>Brevilin A, a sesquiterpene from Centipeda minima, hinders JAK and blocks STAT3 (IC50=10.6μM), inducing apoptosis and autophagy in cancer cells.</p>Formula:C20H26O5Purity:99.97% - >99.99%Color and Shape:SolidMolecular weight:346.42Cerdulatinib hydrochloride
CAS:<p>Cerdulatinib hydrochloride is an oral tyrosine kinase inhibitor targeting JAK1/2/3, TYK2, Syk, and 19 others with IC50 < 200 nM.</p>Formula:C20H28ClN7O3SPurity:99.85%Color and Shape:SolidMolecular weight:482GS-829845
CAS:<p>GS-829845 is a JAK1 inhibitor, the main component of the active metabolite of Filgotinib, which is approximately 10-fold less potent and has a longer half-life</p>Formula:C17H19N5O2SPurity:99.93%Color and Shape:SolidMolecular weight:357.43NVP-BSK805
CAS:<p>NVP-BSK805 (BSK 805) is an ATP-competitive JAK2 inhibitor.</p>Formula:C27H28F2N6OPurity:98%Color and Shape:SolidMolecular weight:490.55Solrikitug
CAS:<p>Solrikitug,Anti-CRLF2 humanized IgG1κ monoclonal antibody.</p>Purity:95%Color and Shape:LiquidZM39923
CAS:<p>ZM39923 is a JAK3 inhibitor (pIC50: 7.1). ZM39923 also effectively inhibits tissue transglutaminase (IC50: 10 nM).</p>Formula:C23H25NOPurity:98%Color and Shape:SolidMolecular weight:331.45(3S,4S)-Tofacitinib
CAS:<p>(3S,4S)-Tofacitinib, a less active enantiomer of tofacitinib, is a Janus kinases inhibitor.</p>Formula:C16H20N6OPurity:98%Color and Shape:SolidMolecular weight:312.37SD-1029
CAS:<p>SD-1029 is a JAK2 inhibitor and a novel Stat3 activation inhibitor that inhibits Stat3 phosphorylation and JAK-STAT signaling.</p>Formula:C25H32Br2Cl2N2O3Color and Shape:SolidMolecular weight:639.25JAK-IN-11
CAS:<p>JAK-IN-11 (R-348) is a potent and selective inhibitor of JAK, has the potential for the skin disorders treatment.</p>Formula:C23H22FN5O4SPurity:99.75%Color and Shape:SolidMolecular weight:483.52JAK-IN-20
CAS:<p>JAK-IN-20: potent oral JAK1,2,3 inhibitor with IC50s 7, 5, 14 nM respectively, good pharmacokinetics, anti-inflammatory in vivo.</p>Formula:C28H30FN7O2Color and Shape:SolidMolecular weight:515.58JAK-2/3-IN-2
CAS:<p>JAK-2/3-IN-2 (Compound 3h) is a potent JAK2 & JAK3 inhibitor with IC50s of 23.85 nM (JAK2) & 18.9 nM (JAK3).</p>Formula:C19H19ClN2OSColor and Shape:SolidMolecular weight:358.89Peficitinib hydrochloride
CAS:<p>Peficitinib HCl (ASP015K) is an oral JAK inhibitor with IC50s: JAK1 (3.9 nM), JAK2 (5.0 nM), JAK3 (0.7 nM), Tyk2 (4.8 nM).</p>Formula:C18H23ClN4O2Color and Shape:SolidMolecular weight:362.86TK4b
CAS:<p>TK4b, a JAK inhibitor, targets leukemia/lymphoid diseases, with IC50s: 18.42 nM (JAK3) & 19.40 nM (JAK2).</p>Formula:C21H22N2O2Color and Shape:SolidMolecular weight:334.41TK4g
CAS:<p>TK4g, a potent JAK inhibitor, has IC50s of 12.61 nM (JAK2) & 15.80 nM (JAK3); promising for lymphoid diseases & leukemia research.</p>Formula:C19H19N3O4SColor and Shape:SolidMolecular weight:385.44JAK-IN-14
CAS:<p>JAK-IN-14 (compound 16) is a specific JAK1 inhibitor. It prevents JAK1 phosphorylation by binding to the active site of JAK in immune, inflammation and cancer.</p>Formula:C19H15FN4OPurity:98.27%Color and Shape:SolidMolecular weight:334.35TyK2-IN-2
CAS:<p>TyK2-IN-2 is a selective inhibitor of TYK2 (IC50s: 7 nM, 0.1 μM, and 0.05 μM for TYK2 JH2, IL-23, and IFNα).</p>Formula:C16H18N6OPurity:98%Color and Shape:SolidMolecular weight:310.35JAK-IN-18
CAS:<p>"JAK-IN-18: potent JAK inhibitor for eye, skin, respiratory disease research (WO2018204238A1, comp 1)."</p>Formula:C27H28F2N6O3Color and Shape:SolidMolecular weight:522.55JAK3-IN-12
CAS:<p>JAK3-IN-12 (compound 15k) is a potent inhibitor of JAK3 (IC50: 9.5 nM) and can be used in the study of rheumatoid arthritis.</p>Formula:C19H19N5O4SColor and Shape:SolidMolecular weight:413.45Tyk2-IN-5
CAS:<p>Tyk2-IN-5 is a selective and orally active inhibitor of Tyk2 JH2 (Ki: 0.086 nM for Tyk2 JH2; IC50: 25 nM for IFNα).</p>Formula:C21H19FN8O2Purity:98%Color and Shape:SolidMolecular weight:434.43EP009
CAS:<p>EP009, a novel, selective, and orally active inhibitor of JAK3, induces therapeutic response in T-cell malignancies.</p>Formula:C14H24O2Color and Shape:SolidMolecular weight:224.34Tyk2-IN-7
CAS:<p>Tyk2-IN-7 is an inhibitor of TYK2 JH2, binds to the TYK2 JH2 domain (IC50: 0.00053 μM; Ki.app: 0.00007 μM).</p>Formula:C18H15D3N6O3SPurity:98%Color and Shape:SolidMolecular weight:401.46MS-1020
CAS:<p>MS-1020 inhibits JAK3/STAT3, blocks active JAK3, suppresses JAK3/STAT5 signaling, and targets STAT3 in certain cells.</p>Formula:C21H18N2O3Purity:98%Color and Shape:SolidMolecular weight:346.381,2,3,4,5,6-Hexabromocyclohexane
CAS:<p>Inhibits JAK2 autophosphorylation; non-cytotoxic at 100μM; 1μM reduces activity by 50%, 50μM nearly abolishes it.</p>Formula:C6H6Br6Purity:98%Color and Shape:SolidMolecular weight:557.54

